HomeMarket News Goldman Sachs Reinstates Buy Rating on 4D Molecular Goldman...

Goldman Sachs Reinstates Buy Rating on 4D Molecular Goldman Sachs Reinstates Buy Rating on 4D Molecular, Anticipates Upcoming Catalysts

Actionable Trade Ideas

always free

Bull and Bear made of Financial Newspaper


After deliberating, Goldman Sachs has decided to reinstate its buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT). The renowned investment bank points to upcoming catalysts as the impetus behind its decision.

Goldman Sachs expressed optimism about the potential for shares to soar, underlining that the catalysts include 24-week data for 4D-150 in wet AMD and diabetic macular edema in the second half of the year. Additionally, the FDA’s feedback on aerosol 4D-710 in modulator ineligible/intolerant cystic fibrosis and modulator combinations in Q1, and data submission in Q2 to lift the clinical hold on 4D-310 in Fabry disease were cited as pivotal drivers.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.